Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
about
The Cloning and Expression of Human Monoclonal Antibodies: Implications for Allergen ImmunotherapyNasal polyposis: current trendsTailored therapy for severe asthmaHuman immunoglobulin E flexes between acutely bent and extended conformations.Two potential therapeutic antibodies bind to a peptide segment of membrane-bound IgE in different conformationsAllergic rhinitis: evidence for impact on asthmaAccelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells.Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescentsPathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab.Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.Janus kinase-3 dependent inflammatory responses in allergic asthmaLong-term benefits of omalizumab in a patient with severe non-allergic asthmaUpdate on optimal use of omalizumab in management of asthma.CD2 identifies a monocyte subpopulation with immunoglobulin E-dependent, high-level expression of Fc epsilon RIPediatric asthma: natural history, assessment, and treatmentAn epigenome-wide association study of total serum immunoglobulin E concentration.Perinatal gene-gene and gene-environment interactions on IgE production and asthma development.T helper 1 cells stimulated with ovalbumin and IL-18 induce airway hyperresponsiveness and lung fibrosis by IFN-gamma and IL-13 productionModern approaches to therapeutic vaccination as treatment for type 1 respiratory hypersensitivity (allergy) treatment.Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.The development of allergic inflammationAnti-IgE and chemotherapy: a critical appraisal of treatment options for severe asthma.Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development.IL-33-dependent induction of allergic lung inflammation by FcγRIII signaling.Apoptosis, airway inflammation and anti-asthma therapy: from immunobiology to clinical application.Omalizumab in the treatment of severe asthma: efficacy and current problems.IgE mediated sensitisation to aeroallergens in an asthmatic cohort: relationship with inflammatory phenotypes and disease severity.Allergic rhinitis in women.Critical and direct involvement of the CD23 stalk region in IgE binding.Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency.Impact of comorbidities on asthma.Immunoglobulin E receptor signaling and asthmaImmunoglobulin E-binding autoantigens: biochemical characterization and clinical relevance.IgE and mast cells in allergic disease.Targeting eosinophils in allergy, inflammation and beyond.Complement components as potential therapeutic targets for asthma treatment.Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid.Nebulization as a delivery method for mAbs in respiratory diseases.Emerging biologics for the treatment of chronic rhinosinusitis.Role of biologics in intractable urticaria.
P2860
Q26771289-57616A9E-10D1-43DD-B7A7-AD94363D1A4EQ26866087-EA2C1B11-82CE-4C86-838C-7469A29B6449Q27016035-D8D4B0D3-0F1F-4A4B-9387-D48A00EA99BEQ27682236-3741A951-9303-4767-8EEE-C137641A4F72Q27688964-8BFCFF63-73ED-4359-ABE8-DB158B2ECC00Q33265228-94F04CF4-C644-48B1-9FC6-1543AB12B587Q33850604-FC3E0932-5978-49F7-8044-DB2C7BE1F9F3Q34627140-D5A18375-CE4B-4C3B-A00F-589A91A42D00Q34924787-452C88E3-413D-429A-900D-777CB8BE9F36Q34979344-225E810D-EFF8-4795-B935-34CC5FBF5F9EQ35031161-AB4C1C20-7FEF-4FA5-93D1-1DD810A30009Q35078215-B53570FD-8687-446E-AFB0-2F1CABDAF755Q35117827-CABFD247-997C-4AB4-968C-BCB625C17682Q35167144-5A2EFCBC-52B5-487A-AC80-5737213A2277Q35211797-8AC2447C-D36A-48CC-9FCC-605C83AD98C2Q35561353-8E7DE5E5-C24E-4219-B391-4DF64C1BE9F4Q35821440-AA0D5915-A8B6-49E6-BB95-5139B44A8601Q35990342-1AA571E8-D261-45A2-BD13-41FF139D08FBQ36383791-968EA419-A22F-4A4D-B3C6-4B06D6594BEDQ36565528-05488331-F146-4759-AD59-63D72BD214E7Q36613696-E7947E4F-C2AF-4DFF-BBA7-39F6A829E1B0Q36765775-CB2F4F90-6282-49D3-9670-7B8E93D4C8F3Q36767393-3E762E67-AEB9-473C-A7E0-033A8ED437DDQ36793403-A339F75B-1F7D-4A45-B7E5-405F92FAE998Q37052175-8C39CD8B-0D8C-4EBE-B14A-1CC017D3C44DQ37362658-13B9E8C5-7810-46A3-88BE-0398992A8AECQ37391767-1DE142F9-593E-4B20-8D9E-DAC75A6EAC90Q37608446-68478E48-AB50-45DF-B0B6-51284211E301Q37660384-67FF51CD-676B-453C-B56E-8BE2A01A933AQ37698945-F67DBAAB-05E2-483C-AC2E-CA2676959E07Q37754787-D8F48EC7-660F-471B-9DA8-033DA3276F0BQ37907670-E50B7786-8382-4441-84BB-24BDF2C18D9AQ37957215-B5505687-A863-4476-986C-59AA29E33E0EQ38007829-E896A061-9D82-45DD-BE4A-D8DEF66A2ABDQ38075409-BCEE9F14-2547-42D2-BF29-C89AC1A7BA1BQ38182225-9364F497-8265-4518-8CF4-BFDA2BCB015FQ38213200-A892C73D-18F2-47B5-B672-5AF6327AF4A8Q38306677-982F09ED-A4EE-422F-9628-74254E2F6495Q38344266-8A0D797B-523B-4025-BB25-44B8EB773A2BQ38450662-7EBE2E43-0050-4A5A-A451-59B86E082A7A
P2860
Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Anti-immunoglobulin E treatmen ...... ctivity and clinical efficacy.
@ast
Anti-immunoglobulin E treatmen ...... ctivity and clinical efficacy.
@en
Anti-immunoglobulin E treatmen ...... ctivity and clinical efficacy.
@nl
type
label
Anti-immunoglobulin E treatmen ...... ctivity and clinical efficacy.
@ast
Anti-immunoglobulin E treatmen ...... ctivity and clinical efficacy.
@en
Anti-immunoglobulin E treatmen ...... ctivity and clinical efficacy.
@nl
prefLabel
Anti-immunoglobulin E treatmen ...... ctivity and clinical efficacy.
@ast
Anti-immunoglobulin E treatmen ...... ctivity and clinical efficacy.
@en
Anti-immunoglobulin E treatmen ...... ctivity and clinical efficacy.
@nl
P2093
P2860
P1476
Anti-immunoglobulin E treatmen ...... ctivity and clinical efficacy.
@en
P2093
Bousquet J
Djukanović R
P2860
P304
P356
10.1111/J.1365-2222.2005.02191.X
P577
2005-04-01T00:00:00Z